24P A phase II trial of docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial carcinoma after staging surgery

The purpose of this study was to evaluate the efficacy docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy after staging surgery in high-risk endometrial cancer patients. This a prospective, phase 2, multicenter clinical trial. Eligible patients included surgically staged stage I-II with factors and III-IV cancer. Three cycles consisting docetaxel (70 mg/m2) cisplatin (60mg/m2) started within 5 weeks surgery. Pelvic (45-50.4Gy) 4 chemotherapy. primary endpoint progression-free survival (PFS). A total 67 were enrolled but 9 excluded. Median age 54 years (range, 31-73 years). Forty (69%) had endometrioid adenocarcinoma. Stage IIIC (15%), IVA 15 (26%), IVB 11 (19%). Staging performed open 27 (46%), laparoscopic 23 (40%), robotic 8 (14%). Grade 3 hematologic toxicity reported 26 43 patients, grade non-hematologic 13 After median follow-up 58 months 2-101 months), recurrence 2 them died disease. PFS (± SE) 90% 4%), 84.3% 4.8 %), 79.9% 5.5 %) at 1, 3, year, respectively. Overall 98.3% 1.7%), 96.2%, 2.6%), 96.2 2.6%) Endometrial high risk could benefit from adjuvant using manageable toxicities. Further studies are needed incorporation biological agents estimate real these treatment strategy.